

**AMENDMENT OF NIAID SOLICITATION**  
**"In Vitro and Animal Models for Emerging Diseases and Biodefense"**

**Solicitation Number:** RFP NIH-NIAID-DMID-03-39

**Amendment Number:** Four (4)

**Amendment Issue Date:** Thursday, September 25, 2003

**Proposal Due Date: (UNCHANGED)** **Tuesday, February 4, 2003 at 4:00 PM Local Time**

**Issued By:** Paul D. McFarlane  
Senior Contracting Officer  
NIAID, NIH, DHHS  
Contract Management Branch, DEA  
6700-B Rockledge Drive  
Room 2230, MSC 7612  
Bethesda, Maryland 20892-7612

**Point of Contact:** Paul D. McFarlane, Contracting Officer  
E-Mail: [pm24v@nih.gov](mailto:pm24v@nih.gov)

**Amendment Issued To:** **All competitive range Part A through F Offerors**

**The above numbered solicitation is amended as set forth below. The hour and date specified for receipt of proposals HAS NOT BEEN EXTENDED. Competitive Offerors shall acknowledge receipt of this amendment by sending an e-mail or letter to the point of contact above no later than Monday, September 29, 2003 at 4 PM EST.**

**PURPOSE OF AMENDMENT:**

This amendment informs the competitive range Offerors for all six (6) lettered Parts A through F to this solicitation that NIAID has determined a new priority award order for these Parts.

NIAID has determined that contract awards to Offerors eligible for lettered Part-C "Small Animal Models for Selected Pathogens, including GLP Studies" and Part-D "Non-human Primate Models for Selected Pathogens, including GLP Studies" shall be accomplished no later than September 30, 2003.

Because of changed scientific priorities within the Division of Microbiology and Infectious Diseases (DMID), NIAID, contract awards for lettered Part-A "In Vitro Screens for Antimicrobial Activity", Part-B "Clinical Isolate Panels for Selected Bacterial Pathogens", Part-E "Safety and Immunogenicity Testing for Vaccines" ; and F "Safety/Toxicology and Pharmacology Testing for Therapeutics" have been deferred to the Federal Government's fiscal year 2004, dependent upon each Part's scientific priority and the availability of funds.

**END OF AMENDMENT #4 TO RFP NIH-NIAID-DMID-03-39**